Patents by Inventor Tohru Tanami
Tohru Tanami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7763652Abstract: A prostaglandin derivative represented by Formula (I): wherein X is a halogen atom in the ?- or ?-substitution, Y is an ethylene group, a vinylene group or an ethynylene group, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with a C1-4 straight or branched chain alkyl group or a C4-13 cycloalkylalkyl group, R2 is a hydrogen atom or a CO2R3 group (R3 is a hydrogen atom, a C1-4 straight or branched chain alkyl group or a C2-4 straight or branched chain alkenyl group), n is an integer of 1 to 4 and p is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: July 11, 2003Date of Patent: July 27, 2010Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Makoto Yagi, Naoya Ono
-
Patent number: 7718701Abstract: A method of treating atopy-evoked pruritic symptoms by administering a prostaglandin derivative.Type: GrantFiled: August 7, 2003Date of Patent: May 18, 2010Assignees: Taisho Pharmaceutical Co., Ltd., Fumi SatoInventors: Fumie Sato, Iwao Arai, Norikazu Takano, Tohru Tanami, Makoto Yagi
-
Publication number: 20060270740Abstract: A prostaglandin derivative represented by the formula (wherein X is a halogen atom; Y is ethylene group, vinylene group or ethylylene group; Z is a group represented by —(CH2)m, —O(CH2)n— or —S(O)p—(CH2)n— (m is an integer of 0 to 3; n is an integer of 0 to 2; and p is an integer of 0 to 2); R1 is a hydrogen atom, a C1-5 alkyl group or a substituted C1-5 alkyl group; R2 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted by C1-4 alkyl group or C4-15 cycloalkylalkyl group; and R3 is a hydrogen atom, a halogen atom or a C1-5 alkyl group or a substituted C1-5 alkyl group), a pharmaceutically acceptable salt thereof or a hydrate thereof which has an excellent antagonism to prostaglandin DP receptor and, therefore, is useful against diseases such as allergic rhinitis, nasal obstruction, asthma, allergic conjunctivitis, systemic mastocytosis and disorder of systemic mast cell activation.Type: ApplicationFiled: February 19, 2004Publication date: November 30, 2006Inventors: Fumie Sato, Tohru Tanami, Naoya Ono, Makoto Yagi, Takayuki Seki, Mariko Sato
-
Publication number: 20060094788Abstract: A prostaglandin derivative represented by Formula (I): wherein X is a halogen atom in the ?- or ?-substitution, Y is an ethylene group, a vinylene group or an ethynylene group, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with a C1-4 straight or branched chain alkyl group or a C4-13 cycloalkylalkyl group, R2 is a hydrogen atom or a CO2R3 group (R3 is a hydrogen atom, a C1-4 straight or branched chain alkyl group or a C2-4 straight or branched chain alkenyl group), n is an integer of 1 to 4 and p is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: July 11, 2003Publication date: May 4, 2006Inventors: Fumie Sato, Tohru Tanami, Makoto Yagi, Naoya Ono
-
Publication number: 20050038259Abstract: A hydroxyeicosenoic acid analog represented by the following Formula (I), the bond ? represents a cis-vinylene group or an ethynylene group; Y represents CH2, O or S(O)p wherein p is 0, 1 or 2; m represents an integer of 1 to 4 inclusive; n represents an integer of 0 to 3 inclusive; the sum of m and n is an integer of 3 to 7 inclusive; R1 represents a C1-4 alkyl group or a C3-8 cycloalkyl group; R2 represents a hydrogen atom or a methyl group; R3 represents COR4, a nitrile group, a halogen atom, a tetrazole group or a thiazolidinedione group; R4 represents OR6, NHR6, N(OH)R6, NHSO2R5, glycerol or functionalized glycerols; R5 represents a C1-15 alkyl group, a C6-10 aryl group or a C7-14 aryl group substituted with alkyl groups, halogens or amino groups; R6 represents a hydrogen, a C1-10 alkyl group or a C1-10 alkyl group substituted with a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof. The compounds of the present invention are useful as an elastase release inhibitor.Type: ApplicationFiled: September 9, 2002Publication date: February 17, 2005Inventors: John Falck, Noriyuki Miyata, Naoya Ono, Tomomichi Chonan, Hitomi Hirano, Yoshihisa Toda, Tohru Tanami, Shigeru Okuyama
-
Publication number: 20050020680Abstract: A hydroxyfattysulfonic acid analog represented by Formula (I): wherein X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH2 or S(O)pCH2 wherein p is 0, 1 or 2; m is an integer of 1 to 5 inclusive; n is an integer of 0 to 4 inclusive; R1 is a C1-8 alkyl group, a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with an aryl group or a C1-4 alkyl group substituted with an aryloxy group; R2 is a hydrogen atom or a methyl group; R1 and R2 together with the carbon atom to which they are attached may form a C3-8 cycloalkyl group; R3 is a hydrogen atom or a C2-8 acyl group; R4 is OR5 or NHR6, wherein R5 is a hydrogen atom, a C1-4 alkyl group, an alkali metal, an alkaline earth metal or an ammonium group and R6 is a hydrogen atom or a C1-4 alkyl group; or a pharmaceutically acceptable salt or a hydrate thereof.Type: ApplicationFiled: September 9, 2002Publication date: January 27, 2005Inventors: John Falck, Noriyuki Miyata, Naoya Ono, Tomomichi Chonan, Hitomi Hirano, Yoshihisa Toda, Tohru Tanami, Shigeru Okuyama
-
Publication number: 20050009917Abstract: A pharmaceutical preparation for preventing or treating pruritic symptoms which contains as an effective ingredient a prostaglandin derivative represented by formula [1] wherein X1 and X2 which are different from each other represent a hydrogen atom, a halogen atom or a hydroxyl group; Y is an ethylene group, a vinylene group or an ethynylene group; Z is the formula (CH2)kA(CH2)hB(CH2)q, (CH2)kA(CH2)rA?(CH2)t (CH2)kB(CH2)hB?(CH2)q or (CH2)k-1B?(CH2)q-1A? wherein k is an integer of 1 to 4, h is an integer of 0 to 4, q is an integer 1 to 4, r is an integer of 0 to 4, and t is an integer of 0 to 2; A and A? which may be the same or different represent an ethylene group, a vinylene group or an ethynylene group; B and B? which may be the same or different represent an oxygen atom or a group represented by the formula S(O)u wherein u is an integer of 0 to 2; W1 is a hydroxyl group, a C1-10 alkyloxy group, a C3-10 cycloalkyloxy group, an aryloxy group or an arylalkyloxy group; W2 is a C1-10 alkyl grouType: ApplicationFiled: August 7, 2003Publication date: January 13, 2005Inventors: Fumie Sato, Iwai Arai, Norikazu Takano, Tohru Tanami, Makoto Yagi
-
Publication number: 20040266880Abstract: The pharmaceutical preparation of the invention, which comprises a prostaglandin or a pharmaceutically acceptable salt thereof as an effective ingredient, has an antipruritic effect with fewer side effects. It is particularly effective in controlling the itch sensation accompanying atopic symptoms.Type: ApplicationFiled: April 19, 2004Publication date: December 30, 2004Inventors: Fumie Sato, Iwao Arai, Norikazu Takano, Tohru Tanami, Makoto Yagi
-
Patent number: 6822112Abstract: A prostaglandin derivative represented by the formula: wherein X is a halogen atom, R1 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 0 to 5, and Y is a group represented by the formula: wherein R2 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C1-4 alkyl group substituted with C3-10 cycloalkyl group(s), a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group or a bridged cyclic hydrocarbon group, or a group represented by the formula: wherein n is an integer of 1 to 8; a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: February 5, 2002Date of Patent: November 23, 2004Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi
-
Patent number: 6740772Abstract: A prostaglandin derivative represented by the formula: wherein X is a halogen atom in the &agr;- or &bgr;-position, Y is an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formula: O(CH2)n, S(O)p(CH2)n, O(CH2)qO(CH2)r, O(CH2)qS(O)p(CH2)r, S(O)p(CH2)qS(O)p(CH2)r or S(O)p(CH2)qO(CH2)r (wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1), R1 is a C3-10 cycloalkyl group, a C1-4 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-4 alkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, and m is 0, 1 or 2], a pharmaceutically acceptable salt thereof or a hydrate thereof. The present invention is to provide novel PG derivatives having an excellent PGD2-like agonistic activity and a sleep-inducing action.Type: GrantFiled: March 11, 2002Date of Patent: May 25, 2004Assignees: Taisho Pharmaceutical Co., Ltd., Fumie SatoInventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi, Hitomi Hirano
-
Patent number: 6613932Abstract: A prostaglandin derivative represented by the formula: [wherein X is CH2, O or S(O)q1, Y is an ethylene group, a vinylene group, an ethynylene group, O(CH2)t1 or S(O)q2(CH2)t1, Z is an ethylene group, a vinylene group or an ethynylene group, R1 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, R2 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-5 alkyl group, a hydroxy-C1-5 alkyl group, a halogeno-C1-5 alkyl group, a C1-5 alkoxy-C1-5 alkyl group, a C2-4 alkoxycarbonyl-C1-5 alkyl group, a carboxyl-C1-5 alkyl group, a cyano-C1-5 alkyl group, a C1-5 alkyl group substituted with a group represented by the formula: —NR7R8, an acyl group, a group represented by the formula: —(CH2)t2CH(NH2)COOR9, etc., and R3 is a hydrogen atom, a C1-10 alkyl group, etc.], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: March 11, 2002Date of Patent: September 2, 2003Assignees: Taisho Pharmaceutical Co., Ltd., Fumie SatoInventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi, Hitomi Hirano
-
Patent number: 6482990Abstract: A prostaglandin analog represented by Formula (I): [wherein A is an ethylene group, a vinylene group or an ethynylene group, Y1 and Y2 are the same or different, and each a hydrogen atom, a halogen atom, a cyano group, —CONR3R4 (wherein R3 and R4 are the same or different, and each a hydrogen atom or a C1-6 alkyl group, or R3 and R4 together with the nitrogen atom to which they are attached form a C4-8 cyclic amine), a C1-3 aminoalkyl group, a C1-6 hydroxyalkyl group, NR5R6 (wherein R5 and R6 are the same or different, and each a hydrogen atom or a C1-6 alkyl group), a hydroxyl group, a C1-6 alkoxy group, a C1-9 alkyl group, a C1-6 alkyl group substituted with halogen(s), a C1-5 acyl group or COOR7 (wherein R7 is a hydrogen atom, a C1-6 alkyl group or a phenyl group), R1 and R2 are the same or different, and each a hydrogen atom, a halogen atom, a C1-9 alkyl group or a C1-6 alkyl group substituted with halogen(s), m is an integer of 0 to 6, and n is an integer of 0 to 3], a pType: GrantFiled: March 4, 2002Date of Patent: November 19, 2002Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi
-
Patent number: 6455584Abstract: To provide a prostaglandin derivative represented by the formula: wherein A is an ethylene group, a vinylene group, an ethynylene group, O(CH2)q or S(O)r(CH2)q, R1 is a C3-10 cycloalkyl group, a C1-4 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-4 alkyl group, a C1-10 alkyl group, a C1-10 alkyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkenyl group, a C2-10 alkenyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkynyl group, a C2-10 alkynyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s) or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 5, n is an integer of 1 to 4, p is 0, 1 or 2, q is an integer of 1 to 5 and r is 0, 1 or 2; a pharmaceutically acceptable salt thereof or a hydrate thereof exhibit excellent action in inhibiting the growth of vascular smooth muscle and is useful as a drug for inhibition of restenosis after perType: GrantFiled: January 4, 2002Date of Patent: September 24, 2002Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi, Hitomi Hirano
-
Patent number: 6395786Abstract: A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH2)m, a cis-vinylene group or a phenylene group, Z is an ethylene group, a trans-vinylene group, OCH2 or S(O)nCH2, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 3, and n is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: November 27, 2000Date of Patent: May 28, 2002Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Kazuya Kameo, Kenji Yamada, Shigeru Okuyama, Naoya Ono
-
Patent number: 6329539Abstract: A prostaglandin derivative represented by the formula: wherein X is a halogen atom, n is an integer of 1 to 5, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, and R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 27, 2000Date of Patent: December 11, 2001Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Kazuya Kameo, Kenji Yamada, Shigeru Okuyama, Naoya Ono
-
Patent number: 5648526Abstract: Object: To produce E-prostaglandins in a high yield and in a short time with suppressed formation of isomers.Structure: A process for preparing E-prostaglandins represented by the formula: ##STR1## (wherein A, R.sup.6 and R.sup.7 represent respectively an arbitrary group which does not participate in the reaction; B represents a vinylene or ethynylene group; and R.sup.4 and R.sup.5 may be the same or different from each other and each represents a hydrogen atom or a protective group of the hydroxyl group) which comprises reacting allyl esters of E-prostaglandins represented by the formula: ##STR2## (wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents a hydrogen atom or a lower alkyl group; R.sup.3 represents a hydrogen atom, a lower alkyl group, an alkenyl group or an aryl group; and A, B, R.sup.4, R.sup.5, R.sup.6 and R.sup.Type: GrantFiled: July 29, 1994Date of Patent: July 15, 1997Assignees: Taisho Pharmaceutical Co., Ltd., Fumie SatoInventors: Fumie Sato, Takehiro Amano, Kazuya Kameo, Tohru Tanami, Masaru Mutoh, Naoya Ono, Jun Goto
-
Patent number: 5639899Abstract: Object: To provide novel prostaglandin E.sub.1 analogues which have more excellent pharmaceutical effects, longer duration of the effects and less side-effects than the prior art prostaglandin E.sub.1 's.Constitution: A PGE.sub.1 analogue represented by the formula: ##STR1## (wherein A is a vinylene group or an ethynylene group, R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an allyl group, R.sup.2 is a branched aliphatic hydrocarbon group having 5 to 10 carbon atoms), or a salt thereof.Type: GrantFiled: October 19, 1993Date of Patent: June 17, 1997Assignees: Taisho Pharmaceutical Co., Ltd., Fumie SatoInventors: Fumie Sato, Takehiro Amano, Kazuya Kameo, Tohru Tanami, Masaru Mutoh, Naoya Ono, Jun Goto
-
Patent number: 5599838Abstract: A prostaglandin derivative represented by the formula: ##STR1## wherein X is halogen atom R.sup.1 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and R.sup.2 is a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkylmethyl group having 4 to 10 carbon atoms or a cycloalkylethyl group having 5 to 12 carbon atoms, or a salt thereof, which has an excellent lowering action of intraocular pressure and improving actions of renal diseases, ischemic heart diseases and heart failure.Type: GrantFiled: February 23, 1996Date of Patent: February 4, 1997Assignees: Taisho Pharmaceutical Co., Ltd., Fumie SatoInventors: Fumie Sato, Takehiro Amano, Kazuya Kameo, Tohru Tanami, Masaru Mutoh, Naoya Ono, Jun Goto
-
Patent number: 5583158Abstract: A prostaglandin E.sub.1 analogue represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; and X is an oxygen atom and R.sup.2 represents ##STR2## or X is a sulfur atom and R.sup.2 represents ##STR3## The compound has a strong and prolonged inhibitory action for platelet aggregation and is useful for treatment of various thrombotic diseases including peripheral circulatory disturbance.Type: GrantFiled: April 19, 1995Date of Patent: December 10, 1996Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Takehiro Amano, Kazuya Kameo, Tohru Tanami, Masaru Mutoh, Naoya Ono, Jun Goto
-
Patent number: 5545666Abstract: A prostaglandin derivative represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, and R.sup.2 represents a cyclohexyl group or a cyclopentylmethyl group. This compound has physiological activities such as platelet aggregation-inhibiting action, renal blood vessel and coronary blood vessel-dilating actions and the like, and is useful for treatment of renal failure and diseases of circulatory organs.Type: GrantFiled: April 19, 1995Date of Patent: August 13, 1996Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Takehiro Amano, Kazuya Kameo, Tohru Tanami, Masaru Mutoh, Naoya Ono, Jun Goto